La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Inventiva a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Inventiva..

Inventiva (NASDAQ:IVA) Azioni, Catena delle Opzioni

INVENTIVA SA - ADR

Inventiva

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Inventiva S.A. - American Depository Shares

Inventiva SA

Alpha Architect International Quantitative Value ETF

Invesco AT1 Capital Bond UCITS ETF - USD Acc

INVESTCORP AI ACQ CRP UTS by Investcorp AI Acquisition Corp.

Investcorp AI Acquisition Corp

Investcorp AI Acquisition Corp Warrants (01/06/2028)

News

Press Releases

Inventiva receives $10 million milestone payment from CTTQ

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

Half-Year Review of Inventiva's Liquidity Contract with  Kepler Cheuvreux

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Inventiva to Participate in Upcoming September Investor Conferences

Inventiva to Host Analyst and Investor Event on October 8, 2025

Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

IVEVF

PARIS:IVA

Absci

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Akebia Therapeutics

CareDx

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Gyre Therapeutics

I-MAB

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kodiak Sciences

Keros Therapeutics

MeiraGTx Hldgs

Monopar Therapeutics

Myriad Genetics

Nurix Therapeutics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Palvella Therapeutics, Inc. - Common Stock

Comments

Inventiva

Inventiva (IVA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO